Table 1

Blood parameters and clinical bleeding symptoms in homozygous carriers of the novel mutations S381F and R113X in CalDAG-GEFI

P1 (S381F)P1 (R113X)P2 (R113X)
WBC × 109/L 7.2 ± 1.2 8.0 ± 0.2 7.9 ± 1.1 
RBC × 1012/L 4.8 ± 0.4 3.9 ± 0.1 4.6 ± 0.1 
Hb, g/dL 11.4 ± 1.9 10.9 ± 0.6 12.5 ± 0.5 
Hct (%) 37.7 ± 8.9 32.9 ± 2.5 38.5 ± 0.5 
Platelets × 109/L 351.5 ± 84.1 182.0 ± 9.9 246.0 ± 22.6 
MPV, fL 8.5 ± 0.9 10.1 ± 2.2 10.0 ± 3.0 
PFA-100 CT (s)    
 Collagen/epinephrine >300 >300 >300 
 Collagen/ADP >300 244 275 
Location of bleeding and score    
 Epistaxis 
 Cutaneous symptoms — 
 Minor wounds — 
 Oral cavity bleeding — — 
 Gastrointestinal bleeding  
 Final bleeding score 10 
P1 (S381F)P1 (R113X)P2 (R113X)
WBC × 109/L 7.2 ± 1.2 8.0 ± 0.2 7.9 ± 1.1 
RBC × 1012/L 4.8 ± 0.4 3.9 ± 0.1 4.6 ± 0.1 
Hb, g/dL 11.4 ± 1.9 10.9 ± 0.6 12.5 ± 0.5 
Hct (%) 37.7 ± 8.9 32.9 ± 2.5 38.5 ± 0.5 
Platelets × 109/L 351.5 ± 84.1 182.0 ± 9.9 246.0 ± 22.6 
MPV, fL 8.5 ± 0.9 10.1 ± 2.2 10.0 ± 3.0 
PFA-100 CT (s)    
 Collagen/epinephrine >300 >300 >300 
 Collagen/ADP >300 244 275 
Location of bleeding and score    
 Epistaxis 
 Cutaneous symptoms — 
 Minor wounds — 
 Oral cavity bleeding — — 
 Gastrointestinal bleeding  
 Final bleeding score 10 

Values are mean ± standard deviation from 2 different complete blood counts separated by at least 2 years. The table reflects the clinically significant bleeding for each symptom, grading the bleeding severity from 0 (absence of symptoms) to 4. The final bleeding score was generated by summing the severity of all bleeding symptoms reported by the patient.16 

CT, closure time; Hb, hemoglobin; Hct, hematocrit; MPV, mean platelet volume; P1, proband 1; PFA-100, platelet function analyzer 100; RBC, red blood cell; WBC, white blood cell.

or Create an Account

Close Modal
Close Modal